CD276 and neoplasm: Therefore, novel therapeutic approaches in NB patients aim to restore the NK cytotoxicity by blocking the immune checkpoint axes or administering in vitro chimeric antigen receptor (CAR) engineered T or NK cells specific for tumor-associated antigens such as GD2 [23,24] or B7-H3 [25].